Parkinson's Gut Microbiome Shifts May Lower Treatment Costs

New research suggests targeting gut bacteria could reduce Parkinson's treatment costs through simpler interventions.

Nagoya University researchers compared fecal samples from 94 Parkinson's patients and 73 healthy controls across four countries in 2024. They found disrupted metabolic pathways for riboflavin (B2) and biotin (B7) synthesis in patients, alongside reduced short-chain fatty acids and polyamines linked to intestinal mucus thinning. Both the Belgian GUT-PARFECT trial (46 patients) and Chinese Zhengzhou University trial (72 patients) showed donor stool transplants improved motor function—by 5.8 points after 12 months versus 2.7 points in placebo, and 3.8 points after 35 weeks versus minimal change in placebo. Nearly half of transplant recipients achieved clinically meaningful motor improvements after 35 weeks versus about 20% in placebo. The trials demonstrated reduced harmful bacteria and stronger gut linings in transplant groups.

The mechanism centers on gut microbiome disruptions that precede Parkinson's symptoms by up to two decades. Targeting these pathways—through potential riboflavin/biotin supplementation or stool transplants—could shift treatment toward low-cost, accessible interventions. Current Parkinson's therapies often cost thousands annually and require complex medical oversight.

This research moves abundance by hinting at treatments that might avoid expensive pharmaceuticals. If validated, gut-focused approaches could make symptom management more affordable and scalable, especially in resource-limited settings where Parkinson's care is often inaccessible. However, both trials remain phase 2 with small sample sizes, and stool transplants are not yet standard treatment. The source stresses these findings require further verification before clinical application.

Source: ScienceAlert